Literature DB >> 32482767

GRAPPA Treatment Recommendations: Updates and Methods.

Arthur Kavanaugh1,2, Laura C Coates3,4, Danielle A van der Windt3,4, Nadia Corp3,4, Enrique R Soriano3,4.   

Abstract

The development and updating of treatment recommendations for optimal treatment approaches for patients with psoriatic arthritis (PsA) has been an important mission of the Group for Research and Assessment of Psoriasis and PsA (GRAPPA) since its inception. Even though the most recent iteration of the GRAPPA PsA recommendations was completed only a few years ago, there have been many significant advances related to therapies and treatment approaches for PsA since their publication. Because of these advances, the process to update the recommendations again has begun. The standard approaches to guideline (or treatment recommendation) development have also evolved in recent years. Herein, the basis for the approach that will be taken for the next version of the GRAPPA PsA treatment recommendations is reviewed.

Entities:  

Keywords:  GRAPPA; PSORIASIS; PSORIATIC ARTHRITIS; TREATMENT RECOMMENDATIONS

Mesh:

Year:  2020        PMID: 32482767     DOI: 10.3899/jrheum.200126

Source DB:  PubMed          Journal:  J Rheumatol Suppl        ISSN: 0380-0903


  4 in total

Review 1.  Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021.

Authors:  Laura C Coates; Enrique R Soriano; Nadia Corp; Heidi Bertheussen; Kristina Callis Duffin; Cristiano B Campanholo; Jeffrey Chau; Lihi Eder; Daniel G Fernández-Ávila; Oliver FitzGerald; Amit Garg; Dafna D Gladman; Niti Goel; Philip S Helliwell; M Elaine Husni; Deepak R Jadon; Arnon Katz; Dhruvkumar Laheru; John Latella; Ying-Ying Leung; Christine Lindsay; Ennio Lubrano; Luis Daniel Mazzuoccolo; Philip J Mease; Denis O'Sullivan; Alexis Ogdie; Wendy Olsder; Penelope Esther Palominos; Lori Schick; Ingrid Steinkoenig; Maarten de Wit; D A van der Windt; Arthur Kavanaugh
Journal:  Nat Rev Rheumatol       Date:  2022-06-27       Impact factor: 32.286

Review 2.  Comorbidity in Adult Psoriasis: Considerations for the Clinician.

Authors:  Christine Daugaard; Lars Iversen; Kasper Fjellhaugen Hjuler
Journal:  Psoriasis (Auckl)       Date:  2022-06-10

3.  Brodalumab Is Associated with High Rates of Complete Clearance and Quality of Life Improvement: A Subgroup Analysis of Patients with Psoriasis and Concomitant Psoriatic Arthritis.

Authors:  Georgios Kokolakis; Kasper Vadstrup; Jes B Hansen; Jose Manuel Carrascosa
Journal:  Dermatology       Date:  2021-11-25       Impact factor: 5.197

4.  Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial.

Authors:  Dafna D Gladman; Philip J Mease; Paul Bird; Enrique R Soriano; Soumya D Chakravarty; May Shawi; Stephen Xu; Sean T Quinn; Cinty Gong; Evan Leibowitz; Denis Poddubnyy; Lai-Shan Tam; Philip S Helliwell; Arthur Kavanaugh; Atul Deodhar; Mikkel Østergaard; Xenofon Baraliakos
Journal:  Trials       Date:  2022-09-05       Impact factor: 2.728

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.